Hansa Biopharma AB (FRA:24H) Other Financing: €57.88 Mil (TTM As of Mar. 2026)


FRA:24H Hansa Biopharma AB FRA:24H
55 GF Score
Price €3.02
GF Value €2.07
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Hansa Biopharma AB Other Financing?

Hansa Biopharma AB FRA:24H -1.69% 55 Other Financing is €57.88 Mil as of Mar. 2026. GuruFocus rates FRA:24H with a GF Score™ of 55/100 and a GF Value™ of €2.07 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Hansa Biopharma AB's Other Financing for the three months ended in Mar. 2026 was €0.01 Mil.

Hansa Biopharma AB's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €57.88 Mil.

Hansa Biopharma AB Other Financing Historical Data

* Premium members only.

The historical data trend for Hansa Biopharma AB's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansa Biopharma AB Other Financing Chart

Hansa Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Hansa Biopharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 57.88 0.01
FRA:24H
55GF Score
Hansa Biopharma AB FRA:24H
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansa Biopharma AB Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €57.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €57.88 Mil mean?
Hansa Biopharma AB (FRA:24H) has a Other Financing of €57.88 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Hansa Biopharma AB and its competitors.
Is Hansa Biopharma AB's Other Financing too high?
Hansa Biopharma AB's current Other Financing is €57.88 Mil. Overall, Hansa Biopharma AB has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Other Financing compare to VRTX and REGN?
Hansa Biopharma AB's Other Financing of €57.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current Other Financing is €57.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Hansa Biopharma AB (FRA:24H) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.07, compared to a current price of €3.02 — trading 46% above its estimated fair value. The current Other Financing is €57.88 Mil. Hansa Biopharma AB's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Hansa Biopharma AB (FRA:24H), the current Other Financing is €57.88 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansa Biopharma AB (FRA:24H) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of €3.02 is trading 46% above its estimated GF Value™ of €2.07. GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.

Key valuation signals for FRA:24H:

  • Other Financing: €57.88 Mil
  • GF Value™: €2.07 vs. price of €3.02 (46% above fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the FRA:24H stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
55GF Score

Get the complete analysis for FRA:24H

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.02
Price
€2.07
GF Value